|
127 Companies |
|
123 Products |
|
123 Products |
|
59 Mechanisms of Action |
|
6 Trials |
|
3245 News |
|
| «12...678910111213141516...6566» |
- |||| 514G3 / XBiotech
Trial completion: A Study of the Safety and Efficacy of 514G3 in Subjects Hospitalized With Bacteremia Due to Staphylococcus Aureus (clinicaltrials.gov) - Feb 17, 2017
P1/2, N=52, Completed, Sponsor: XBiotech, Inc.
Active, not recruiting --> Completed
- | Enrollment open: Tailored Versus Empiric Therapy for Helicobacter Pylori Treatment (clinicaltrials.gov) - Feb 17, 2017
P4, N=500, Recruiting, Sponsor: Shanghai Jiao Tong University School of Medicine
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- || Enrollment closed: A Phase 1, Randomized, Controlled, Observer-blinded Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Healthy Adults Aged 18 to 49 Years (clinicaltrials.gov) - Feb 17, 2017
P1, N=66, Active, not recruiting, Sponsor: Pfizer
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | apremilast / Generic mfg.
New P2 trial: SMASH: Short-term Safety, Efficacy and Mode of Action of Apremilast in Moderate Suppurative Hidradenitis (clinicaltrials.gov) - Feb 16, 2017
P2, N=20, Recruiting, Sponsor: M.B.A. van Doorn
- | Trial primary completion date, HEOR, Real-world evidence, Real-world: Effect of Xpert MTB/RIF on Patient Outcomes (clinicaltrials.gov) - Feb 16, 2017
P=N/A, N=892, Recruiting, Sponsor: University of North Carolina, Chapel Hill
Recruiting --> Active, not recruiting Trial primary completion date: Jan 2017 --> May 2017
- | New trial: Rapid Strep Testing in Children With Recent Streptococcal Pharyngitis (clinicaltrials.gov) - Feb 16, 2017
P=N/A, N=600, Recruiting, Sponsor: Georgetown University
- Phase classification, Head-to-Head: Line Probe Assay Evaluation Study (clinicaltrials.gov) - Feb 14, 2017
P=N/A, N=888, Completed, Sponsor: Foundation for Innovative New Diagnostics, Switzerland
Trial primary completion date: Jan 2017 --> May 2017 Phase classification: P1/2 --> P=N/A
- | Enrollment closed, Enrollment change, Trial primary completion date: ELIXIR: Evaluation of Lung Clearance Index in Cystic Fibrosis (CF) Patients, Infected With P.Aeruginosa (clinicaltrials.gov) - Feb 13, 2017
P4, N=15, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Phase classification: P1/2 --> P=N/A Recruiting --> Active, not recruiting | N=35 --> 15 | Trial primary completion date: Jan 2017 --> May 2017
- | azithromycin / Generic mfg.
Trial completion: RESCUE-L: Special Investigation Of Azithromycin IV For Legionnaires' Disease (Regulatory Post Marketing Commitment Plan) (clinicaltrials.gov) - Feb 12, 2017
P=N/A, N=20, Completed, Sponsor: Pfizer
Recruiting --> Active, not recruiting | N=35 --> 15 | Trial primary completion date: Jan 2017 --> May 2017 Active, not recruiting --> Completed
- bismuth subcitrate potassium/ metronidazole/tetracycline / Generic mfg.
Enrollment change, Compliance: Safety, Efficacy of Pylera BID Dosing in Eradication of H. Pylori (clinicaltrials.gov) - Feb 12, 2017
P3, N=0, Withdrawn, Sponsor: Forest Laboratories
Active, not recruiting --> Completed N=30 --> 0
- New trial: CATS-CARE: Combining Opioid Addiction Treatment Services With CARe for Infectious Endocarditis (clinicaltrials.gov) - Feb 9, 2017
P=N/A, N=20, Not yet recruiting, Sponsor: Laura Fanucchi
- Trial primary completion date: Comparison of Daily Single Dose Triple and Conventional Triple Therapies for Helicobacter Pylori Infection (clinicaltrials.gov) - Feb 7, 2017
P4, N=200, Recruiting, Sponsor: Zahra Vahdat Shariatpanahi
N=30 --> 0 Trial primary completion date: Jan 2017 --> Apr 2017
- ||||||| AzaSite (1% azithromycin ophthalmic solution) / Sun Pharma, Akorn, Nicox
Trial completion: Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Vehicle for Bacterial Conjunctivitis (C-01-401-003) (clinicaltrials.gov) - Feb 6, 2017
P3, N=685, Completed, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Jan 2017 --> Apr 2017 Recruiting --> Completed
- ||||||| AzaSite (1% azithromycin ophthalmic solution) / Sun Pharma, Akorn, Nicox
Trial completion: Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Tobramycin for Bacterial Conjunctivitis (C-01-401-004) (clinicaltrials.gov) - Feb 6, 2017
P3, N=743, Completed, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Completed Recruiting --> Completed
- Trial primary completion date: Application of GeneXpert on Bronchoscopic Samples in the Clinical Management of Patients Suspicious of TB (clinicaltrials.gov) - Feb 6, 2017
P=N/A, N=200, Recruiting, Sponsor: Chinese University of Hong Kong
Recruiting --> Completed Trial primary completion date: Oct 2016 --> Apr 2017
- Enrollment change, Trial initiation date, Trial primary completion date: Resistant Bacterial Infections in the Early Post LDLT Period (clinicaltrials.gov) - Feb 6, 2017
P=N/A, N=45, Completed, Sponsor: Ain Shams University
Trial primary completion date: Oct 2016 --> Apr 2017 N=35 --> 45 | Initiation date: Jan 2013 --> Jan 2014 | Trial primary completion date: May 2014 --> Nov 2015
- || Trial primary completion date: A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Ascending Intravenous Single Dose and Repeat Dose of GSK3342830 (clinicaltrials.gov) - Feb 3, 2017
P1, N=78, Recruiting, Sponsor: GlaxoSmithKline
N=35 --> 45 | Initiation date: Jan 2013 --> Jan 2014 | Trial primary completion date: May 2014 --> Nov 2015 Trial primary completion date: Dec 2016 --> May 2017
- ||| Trial completion, Enrollment change: Study of Accuracy of New Diagnostic Technology to Guide Rapid Antibiotic Treatment for Serious Infections (clinicaltrials.gov) - Feb 2, 2017
P=N/A, N=2102, Completed, Sponsor: Denver Health and Hospital Authority
Trial primary completion date: Dec 2016 --> May 2017 Recruiting --> Completed | N=1500 --> 2102
- Boostrix (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine) / GSK
Trial primary completion date: Impact of Boostrix™ Maternal Vaccination on Morbidity and Mortality of Pertussis Disease in Infants ≤6 Weeks of Age, in Bogota, Colombia. (clinicaltrials.gov) - Feb 2, 2017
P=N/A, N=1, Recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Completed | N=1500 --> 2102 Trial primary completion date: Nov 2018 --> Jan 2018
- Trial completion, Trial primary completion date: Tuberculosis Recurrence Upon Treatment With Highly Active Antiretroviral Therapy (clinicaltrials.gov) - Feb 2, 2017
P=N/A, N=402, Completed, Sponsor: Centre for the AIDS Programme of Research in South Africa
Trial primary completion date: Nov 2018 --> Jan 2018 Active, not recruiting --> Completed | Trial primary completion date: May 2016 --> Apr 2014
- ||| Trial completion: Substudy of Protocol TB-018 (NCT01755598): Collection and Storage of Biological Samples for Evaluation of Correlates of TB (C-041-972) (clinicaltrials.gov) - Feb 1, 2017
P=N/A, N=3253, Completed, Sponsor: Aeras
Active, not recruiting --> Completed | Trial primary completion date: May 2016 --> Apr 2014 Active, not recruiting --> Completed
- Boostrix (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine) / GSK, Adacel (tetanus toxoid/reduced diphtheria toxoid/acellular pertussis vaccine adsorbed) / Sanofi
Trial primary completion date: Mutliboost: Pertussis and Meningitis C Concomitant Vaccination in Adolescents (clinicaltrials.gov) - Feb 1, 2017
P4, N=800, Recruiting, Sponsor: Public Health England
Active, not recruiting --> Completed Trial primary completion date: Dec 2016 --> Mar 2017
- New trial: Procalcitonin Level as a Surrogate for Catheter-related Blood Stream Bacteremia Among Hemodialysis Patients (clinicaltrials.gov) - Feb 1, 2017
P=N/A, N=28, Recruiting, Sponsor: Benha University
- Sirturo (bedaquiline) / J&J, Pharmstandard
Phase classification, Combination therapy: Early Access of TMC207 in Patients With Extensively Drug Resistant or Pre-XDR Pulmonary Tuberculosis (clinicaltrials.gov) - Feb 1, 2017
P=N/A, N=0, Approved for marketing, Sponsor: Janssen Infectious Diseases BVBA
Trial primary completion date: Dec 2016 --> Mar 2017 Phase classification: P3 --> P=N/A
- | Nuvocid (oritavancin) / Melinta Therap
Enrollment open: Safety of Either a Single or Two IV Doses of Orbactiv in Subjects With ABSSSI (clinicaltrials.gov) - Jan 31, 2017
P4, N=20, Recruiting, Sponsor: The Medicines Company
Phase classification: P3 --> P=N/A Not yet recruiting --> Recruiting
- || Enrollment closed, Trial primary completion date: A Multi-Site Clinical Evaluation of the ARIES Bordetella Assay in Symptomatic Patients (clinicaltrials.gov) - Jan 31, 2017
P=N/A, N=1000, Active, not recruiting, Sponsor: Luminex Molecular Diagnostics
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> Apr 2017
- Altabax (retapamulin) / GSK, Almirall
Enrollment change, Surgery: TOPS-MRSA: Treatment of Patients Colonized With Methicillin-Resistant Staphylococcus Aureus Prior to Bone and Joint Surgery (clinicaltrials.gov) - Jan 31, 2017
P2, N=0, Withdrawn, Sponsor: Bay Pines VA Healthcare System
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> Apr 2017 N=400 --> 0
- Trial primary completion date, HEOR: Quality of Life After Wide Surgical Excision in Patients With Hidradenitis Suppurativa (clinicaltrials.gov) - Jan 31, 2017
P=N/A, N=100, Enrolling by invitation, Sponsor: University of Schleswig-Holstein
N=400 --> 0 Trial primary completion date: Dec 2015 --> Apr 2017
- OligoG CF-5/20 / AlgiPharma
Trial primary completion date: A Study of OligoG in Cystic Fibrosis Subjects With Burkholderia Spp. Infection (clinicaltrials.gov) - Jan 30, 2017
P2, N=15, Active, not recruiting, Sponsor: AlgiPharma AS
Trial primary completion date: Dec 2015 --> Apr 2017 Trial primary completion date: Sep 2016 --> Mar 2017
- Trial primary completion date: A Controlled Smoking Cessation Trial and Prospective Cohort Study of Tuberculosis (TB) Treatment Outcomes (clinicaltrials.gov) - Jan 30, 2017
P=N/A, N=450, Recruiting, Sponsor: Johns Hopkins University
Trial primary completion date: Sep 2016 --> Mar 2017 Trial primary completion date: Jun 2016 --> Jun 2017
- Trial primary completion date: Safety, Tolerability, and Immunogenicity of the Vaccine Candidates ID93 + AP10-602 and ID93 + GLA-SE Administered Intramuscularly in Healthy Adult Subjects (clinicaltrials.gov) - Jan 30, 2017
P1, N=70, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Jun 2016 --> Jun 2017 Trial primary completion date: Mar 2017 --> Aug 2017
- Solithera (solithromycin) / Melinta Therap, Fujifilm Holdings
Trial completion, Trial primary completion date: Genitourinary and Pharyngeal Pharmacokinetics of Solithromycin (clinicaltrials.gov) - Jan 30, 2017
P1, N=28, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Mar 2017 --> Aug 2017 Recruiting --> Completed | Trial primary completion date: Sep 2016 --> Jan 2017
- Rotarix (rotavirus vaccine) / GSK
Enrollment closed: Rota-biome: The Role of the Intestinal Microbiome in Enteric and Systemic Vaccine Immune Responses (clinicaltrials.gov) - Jan 26, 2017
P=N/A, N=63, Active, not recruiting, Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Recruiting --> Completed | Trial primary completion date: Sep 2016 --> Jan 2017 Recruiting --> Active, not recruiting
- ||||| Nuzyra (omadacycline) / Paratek
Enrollment closed, Trial primary completion date: Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13) (clinicaltrials.gov) - Jan 26, 2017
P3, N=750, Active, not recruiting, Sponsor: Paratek Pharmaceuticals Inc
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2017 --> Feb 2017
- Sirturo (bedaquiline) / J&J, Pharmstandard
New trial: TASK-002: Bioequivalence of Bedaquiline 400mg Administered in Crushed Form Compared to Tablet Form in Healthy Male and Female Adults Under Fed Conditions (BDQ Crush Study) (clinicaltrials.gov) - Jan 25, 2017
P=N/A, N=24, Active, not recruiting, Sponsor: International Maternal Pediatric Adolescent AIDS Clinical Trials Group
- flucloxacillin sodium / Generic mfg.
Trial primary completion date: DANCE: Duration of ANtibiotic Therapy for CEllulitis (clinicaltrials.gov) - Jan 24, 2017
P4, N=316, Recruiting, Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2017 --> Feb 2017 Trial primary completion date: Apr 2017 --> Jan 2018
- ||| AERAS-404 / Sanofi
Enrollment closed, Trial primary completion date: Phase 1/II, Safety and Immunogenicity Study of AERAS-404 in BCG-Primed Infants (clinicaltrials.gov) - Jan 24, 2017
P1/2, N=243, Active, not recruiting, Sponsor: Aeras
Trial primary completion date: Apr 2017 --> Jan 2018 Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Dec 2016 --> Dec 2017
- New trial: Effect of Rheumatic Heart Disease on Maternal and Fetal Outcomes (clinicaltrials.gov) - Jan 24, 2017
P=N/A, N=125, Active, not recruiting, Sponsor: Assiut University
- ||||||| Menveo (meningococcal-groups A, C, W-135 and Y oligosaccharide CRM197 conjugate vaccine) / GSK, Bexsero (meningococcal group B vaccine) / GSK
Trial completion, Phase classification: Safety and Immunogenicity of GlaxoSmithKline Biologicals Meningococcal Group B Vaccine When Administered Concomitantly With GlaxoSmithKline Biologicals MenACWY Conjugate Vaccine to Healthy Infants (clinicaltrials.gov) - Jan 23, 2017
P3b, N=750, Completed, Sponsor: GlaxoSmithKline
Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Dec 2016 --> Dec 2017 Active, not recruiting --> Completed | Phase classification: P3 --> P3b
- || Trial primary completion date, Pneumococcal vaccines: System Alignment for VaccinE Delivery (SAVED): Improving Rates of Influenza and Pneumococcal Vaccination Through Patient Outreach, Improved Medical Record Accuracy and Targeted Physician Alerts (clinicaltrials.gov) - Jan 23, 2017
P=N/A, N=30000, Enrolling by invitation, Sponsor: University of Massachusetts, Worcester
Active, not recruiting --> Completed | Phase classification: P3 --> P3b Trial primary completion date: Dec 2016 --> Dec 2017
- |||||||||| New P3 trial: Clinical Study of Recombinant Mycobacterium Tuberculosis ESAT6-CFP10 Allergen for Children (clinicaltrials.gov) - Jan 23, 2017
P3, N=96, Recruiting, Sponsor: Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- | Gohibic (vilobelimab) / Staidson Biopharma, InflaRx
Enrollment open: Studying Complement Inhibition in Patients With Moderate to Severe Hidradenitis Suppurativa (clinicaltrials.gov) - Jan 21, 2017
P2, N=12, Recruiting, Sponsor: InflaRx GmbH
Trial primary completion date: Dec 2016 --> Dec 2017 Not yet recruiting --> Recruiting
- Cubicin (daptomycin) / Merck (MSD)
Trial primary completion date, Monotherapy: Efficacy of Daptomycin Plus Fosfomycin Versus Daptomycin for Treatment of MRSA Bacteremia (clinicaltrials.gov) - Jan 19, 2017
P3, N=206, Recruiting, Sponsor: Miquel Pujol
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2016 --> Dec 2017
- ||| Enrollment closed, Trial primary completion date: A Study of the Safety and Immune Response of 2 Doses of a New Shigella Vaccine in Kenyan Adults (clinicaltrials.gov) - Jan 19, 2017
P2a, N=72, Active, not recruiting, Sponsor: GSK Vaccines Institute For Global Health S.r.l.
Trial primary completion date: Dec 2016 --> Dec 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> Mar 2017
- Enrollment open, Trial primary completion date: UK_DR-TB: Improving the Management of Drug Resistant Tuberculosis in the UK (clinicaltrials.gov) - Jan 19, 2017
P=N/A, N=1282, Recruiting, Sponsor: University College, London
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> Mar 2017 Not yet recruiting --> Recruiting | Trial primary completion date: Mar 2017 --> Oct 2017
- Trial primary completion date, Biopsy: COFFEE: Yield of Cryoprobe vs Flexible Forceps Pleural Biopsy (clinicaltrials.gov) - Jan 18, 2017
P=N/A, N=50, Recruiting, Sponsor: Postgraduate Institute of Medical Education and Research
Not yet recruiting --> Recruiting | Trial primary completion date: Mar 2017 --> Oct 2017 Trial primary completion date: Jun 2016 --> Jun 2017
- |||| linezolid oral / Generic mfg.
Trial completion: ABSSSI: MRX-I Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection (clinicaltrials.gov) - Jan 18, 2017
P2, N=120, Completed, Sponsor: MicuRx
Trial primary completion date: Jun 2016 --> Jun 2017 Active, not recruiting --> Completed
- New trial: Trial of Low-cost Microbiological Water Test Kits (clinicaltrials.gov) - Jan 17, 2017
P=N/A, N=545, Not yet recruiting, Sponsor: London School of Hygiene and Tropical Medicine
- || Synflorix (10-valent pneumococcal conjugate vaccine) / GSK
Trial primary completion date: Post Marketing Surveillance of Synflorix Vaccine Safety Among Infants in Korea (clinicaltrials.gov) - Jan 13, 2017
P=N/A, N=622, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Trial primary completion date: Sep 2014 --> Sep 2015
- Enrollment closed: Persistent Methicillin Resistant Staphylococcus Aureus Eradication Protocol (PMEP) (clinicaltrials.gov) - Jan 13, 2017
P2, N=40, Active, not recruiting, Sponsor: Michael Boyle
Trial primary completion date: Sep 2014 --> Sep 2015 Recruiting --> Active, not recruiting